drugset / Trial / NCT01656070

Vitamin D Supplementation in HIV-infected Youth

NCT01656070

Phase 2 Completed 50 enrolled University of Milan
RandomizedParallel-groupDouble-blindTreatment

Summary

Along with its effects on bone metabolism, vitamin D is an important modulator of the immune system. Experimental studies have shown that the active metabolite of vitamin D \[1,25(OH)2D\] is able to skew the T cell compartment into a more anti-inflammatory state, with inhibition of Th1 and Th17 cells and promotion of Th2 and T regulatory subsets. In the context of HIV infection, in which Th1 subpopulations are devoted to inhibit viral replication, any alteration of the Th1/Th2 balance would be of concern. The aim of this Randomized Controlled Trial is to test wether oral supplementation with cholecalciferol could be able: 1) to improve vitamin D status and, 2) to play an immunomodulatory role, in vertically HIV-infected children and young adults with hypovitaminosis D.

Timeline

Start
2011-04
Primary completion
2012-07
Completion
2012-07

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Cholecalciferol Other / unclassified 100000 iu Oral